Table 1.

Quality measures, overall and by race and ethnicity

Number of Persons	All 93,311	Black 41,297	Latinx 14,301	White 37,713
1. Any antipsychotic drug use	90	90	93	90
2. Any log-acting injectable antipsychotic drug	15	17	14	13
3. Any clozapine use	4.6	2.5	4.7	7.0
4. Antipsychotic adherencea ≥ 80%	49	39	51	59
5. Antipsychotic adherencea ≥ 50%	72	64	76	80
6. No antipsychotic polypharmacy	79	83	78	76
7. Any schizophrenia inpatient discharge	19	20	21	18
8. Follow-up within 7 days	24	23	26	24
9. Follow-up care 30 days	36	34	38	36
10. Any schizophrenia ED visit	3.6	4.4	2.3	3.1
11. Follow-up care within 7 days	37	35	38	39
12. Follow-up care within 30 days	47	44	51	51
13. Any ambulatory mental healthcare visit	99	98	98	99
14. Quarterly ambulatory MH care visits	63	58	66	66
No excessive acute care utilization for:
15. schizophrenia	95	94	95	95
16. mental health	91	91	91	91
17. Any schizophrenia hospitalization	20	20	22	19
18. No 30-day re-admission	77	77	76	77
19. Any MH hospitalization	23	23	24	22
20. No 30-day re-admission	74	74	73	73
21. Any MH psychosocial services	84	85	83	83
22. Quarterly psychosocial services	41	40	37	43
23. Any individual, group, or family psychotherapy	28	36	12	26
Mean number met (SD)	10.0 (2.14)	9.89 (2.21)	10.0 (2.02)	10.2 (2.08)

Note. Entries are percentages except the last row which reports the mean number (SD) of quality measures met. Ordinal metrics include antipsychotic adherence level (items 4 and 5), follow-up after discharge (items 7 + 8 + 9), and follow-up after an emergency department visit (items 10 + 11 + 12); nominal metrics include no re-admission following a schizophrenia hospitalization (items 17 + 18) and no re-admission following a mental health hospitalization (items 19 + 20). ED = emergency department, MH = mental health.

^aMeasured as a percentage of days covered.